12 completed, 2 active not recruiting, 2 terminated, 1 withdrawn. 17 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 12, Active not recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Endocyte: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer Lu-PSMA, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Active not recruiting | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 162 | 2020-08-17 | 2026-06-22 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 201 | 2018-01-29 | 2022-06-13 |
| Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Terminated | Endocyte | 71 | 2017-07-12 | 2021-03-24 |
| Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide - Breast Neoplasms | Phase 2 | Withdrawn | Endocyte | 2014-04-01 | 2014-12-19 | |
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer EC145, EC145 + Docetaxel, Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Endocyte | 203 | 2011-03-01 | 2021-04-01 |
| Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) EC145 - Solid Tumors | Phase 2 | Completed | Endocyte | 1 | 2009-12-31 | 2021-04-08 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) Vintafolide, pegylated liposomal doxorubicin (PLD), EC20 - Ovarian Cancer | Phase 2 | Completed | Endocyte | 162 | 2008-09-01 | 2015-01-07 |
| Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) Vintafolide, Ertafolide - Ovarian Cancer, Endometrial Cancer | Phase 2 | Completed | Endocyte | 49 | 2007-08-01 | 2015-01-07 |
| Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Vintafolide, Etarfolatide - Adenocarcinoma of the Lung | Phase 2 | Completed | Endocyte | 43 | 2007-08-01 | 2015-02-27 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma | Phase 2 | Terminated | Endocyte | 12 | 2007-06-01 | 2012-03-08 |
| FolateScan in Autoimmune Disease FolateScan (Technetium Tc 99mEC20) - Rheumatoid Arthritis, Osteoarthritis | Phase 2 | Completed | Mayo Clinic | 75 | 2006-09-01 | 2010-04-16 |
| Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma Technetium Tc 99m EC20 - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Endocyte | 150 | 2003-11-01 | 2023-07-25 |
| Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor Tc 99m EC20 - Recurrent or Metastatic Cancer, Head and Neck Cancer | Phase 2 | Completed | Endocyte | 40 | 2003-08-01 | 2023-06-22 |
| Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma Tc 99m EC20 - Ovarian Carcinoma, Recurrent Endometrial Carcinoma | Phase 2 | Completed | Endocyte | 16 | 2003-08-01 | 2023-06-22 |
| Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Technetium Tc 99m EC20 - Pituitary Tumors | Phase 2 | Completed | Endocyte | 40 | 2002-09-01 | 2023-06-22 |
| Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma Tc 99m EC20 - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Endocyte | 40 | 2002-08-01 | 2023-06-22 |
Neoplasms (5) · Adenocarcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Endometrial Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Crohn Disease (1) · Head and Neck Neoplasms (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1)
EC145 (6) · Pluvicto (3) · technetium 99m etarfolatide (3) · Docetaxel (1) · Folic Acid (1) · GPI0100 (1) · Interferon-alpha (1) · Interleukin-2 (1) · Introns (1) · Paclitaxel (1) · Premedication (1) · aldesleukin (1) · cabazitaxel (1) · enzalutamide (1) · fluorescein isothiocyanate-keyhole limpet hemocyanin (1)
United States (7) · Australia (3)
Binh Nguyen, MD, PhD (2) · Declan Murphy (1) · Eric L Matteson, M.D., M.P.H. (1) · John Violet (1) · Louise Emmett, MBBS, FRACP (1) · Michael Hofman, A/Prof (1) · Michael S Hofman (1) · Nelson M Oyesiku, MD, PhD (1) · Nelson Oyesiku, MD (1) · Richard A Messmann, MD, MHS, BSc (1) · Siu-Long Yao (1) · Val J Lowe, MD (1)
PMID 18952896, PMID 24127448, PMID 24667717, PMID 31595044, PMID 33581798, PMID 34246328, PMID 34373282, PMID 36261050, PMID 36350899, PMID 37407274, PMID 37891072, PMID 38043558, PMID 38621400, PMID 39956124, PMID 40425844, PMID 40752515, PMID 41956861, PMID 41986500, PMID 42048586